ライフサイエンスコーパス: tumor necrosis factor inhibitor

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 n by steroids, thiopurines, methotrexate, or tumor necrosis factor inhibitors.

2 ransplant recipients, and patients receiving tumor necrosis factor inhibitors.

3 in combination with certain biologic agents (tumor necrosis factor inhibitors and rituximab).

4 halidomide, cyclophosphamide, hemoperfusion, tumor necrosis factor inhibitors, and granulocyte colony

5 lung disease may respond to cyclosporine or tumor necrosis factor inhibitors, and that tumor necrosi

6 along with oral retinoids, methotrexate, and tumor necrosis factor inhibitors as most helpful.

7 d in 20 of 106 patients (18.9%) treated with tumor necrosis factor inhibitors, but did not lead to di

8 drug was more likely with methotrexate than tumor necrosis factor inhibitors, but having 1 or more i

9 hown that in several clinical circumstances, tumor necrosis factor inhibitors can indeed have an incr

10 2.1 (95% CI, 0.55-8.4) in patients receiving tumor necrosis factor inhibitors compared with controls.

11 The introduction of the macromolecule tumor necrosis factor inhibitors etanercept, infliximab,

12 The introduction of tumor necrosis factor inhibitors for patients with ankyl

13 other inflammatory arthritides treated with tumor necrosis factor inhibitors frequently undergo orth

14 The introduction of biologic agents such as tumor necrosis factor inhibitors has changed how we appr

15 The notable success of tumor necrosis factor inhibitors has not only changed th

16 Treatment with tumor necrosis factor inhibitors has not only resulted i

17 As a class, tumor necrosis factor inhibitors have arguably been the

18 Recently, tumor necrosis factor inhibitors have become available f

19 Biologic agents, notably the tumor necrosis factor inhibitors, have effected dramatic

20 paper reviews data from clinical trials with tumor necrosis factor inhibitors in ankylosing spondylit

21 uld be performed to elucidate the effects of tumor necrosis factor inhibitors in Still's disease.

22 Early experience with tumor necrosis factor inhibitors indicates that they may

23 ies of a co-stimulation blocker (abatacept), tumor necrosis factor inhibitor (infliximab), and interl

24 te of malignancy among children treated with tumor necrosis factor inhibitors is worrisome.

25 By contrast, it has been suggested that tumor necrosis factor inhibitors may induce some manifes

26 Information regarding the influence of tumor necrosis factor inhibitors on the risk for postope

27 ble side effects associated with one or more tumor necrosis factor inhibitors, other biologic DMARDs,

28 Medication-related AEs occur less often with tumor necrosis factor inhibitors than with methotrexate.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。